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Abstract: A disease in each single patient can be one of a kind and an individual approach is needed. Tumors are in this 
case particularly risky. The main research problem, as a case study, was to demonstrate the length and com-
position of the current Polish diagnostic process for two most risky conditions: ovarian carcinoma and lung 
cancer, as well as to determine the causes for this. The main goal was to create a new, innovative model for 
time-improved diagnostic processes of ovarian and lung cancer. In order to achieve aims of this research, the 
BPMN and CPM were used. The main result of this study is a model of treatment processes in the indicated 
cases with organizational changes, encompassing all possible types of contact between the patient and the 
healthcare system. The entire diagnostic time for lung and ovarian cancer was shortened about 50%, which 
significantly increases the chances of quick diagnosis and effective treatment. The newly designed and pre-
sented in the text model is an example of organizational innovation where implementation of ICT solutions, 
allows to achieve and even improve an optimal path leading to the development of personalized medicine. 
1 INTRODUCTION 
A disease in each single patient can be one of a kind 
and an individual approach is therefore needed. The 
proper treatment is undertaken with considerable de-
lay. This delay can be divided into three types. The 
first concerns delay in diagnosis caused by too late 
first visit at the primary care physician (PCP) or in-
sufficient knowledge of the PCP to notice certain 
symptoms. The second group of delay results from 
lengthy and rigid workup procedures (overlapping 
delay loop) and introduction of appropriate treatment 
due to accurate decisions. Finally, the third type of 
delay is associated with the reaction of the organism 
to therapy. The economic dimension of these types of 
delay and barriers in treatment cannot be left unno-
ticed. Damage to health caused by neoplasms renders 
the vast human potential, mainly the professional one, 
unexploited, and the costs of treatment and care over 
patients leave a mark in economies, which might 
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threaten the future stability of public finances and 
cause a decrease in Gross National Product (GNP), 
not only in Poland. According to the Polish National 
Cancer Registry (Didkowska et al., 2015), there were 
156.5 thousand new cases of malignancies and 94 
thousand deaths due to such diseases in 2013. The in-
cidence had increased by approximately 4 thousand. 
Malignant tumors constitute the second cause of mor-
tality in Poland. In 2013, these diseases accounted for 
26% of deaths among males and almost 23% among 
females. Malignant tumors are the principal cause of 
premature death (before the age of 65). This phenom-
enon is particularly evident in the female population: 
33% of death in the group of young women and nearly 
49% among middle-aged ones (Didkowska et al., 
2015). In Poland, lung cancer (ICD10: C34) accounts 
for 1/3 of all deaths due to malignant cancers among 
males and 15% among females. Ovarian carcinoma 
(ICD10: C56), in turn, is a cause of 6.2% of all deaths 
due to malignant cancers among Polish women. In 
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2000–2002, one-year survival rates reached 71.9%. 
This value remained similar in 2003–2005 (70.8%) as 
though global innovations could not reach Poland. 
According to the EUROCARE-5 study (Eurocare, 
2014), Poland, with 5-year survival among ovarian 
cancer patients of 34.5%, falls below the European 
value, i.e. 37.6%. Is this not the highest time for the 
implementation of personalized model of treatment in 
these cases? However, in order to do this properly and 
effectively, it is necessary to first review the existing 
process paths in the diagnosis and treatment of these 
diseases. The critical point in the treatment of these 
diseases is the moment of initiation of proper inpa-
tient treatment as well as selection and application of 
individualized therapies. In order to perfect the entire 
process, one must first improve the diagnostic process 
because the moment of initiation and duration of 
proper treatment depends upon the efficiency and ef-
ficacy of diagnosis. This paper, describes a design of 
a processes, starting with the first contact up to the 
conclusion of personalized therapy and a return to so-
cial and economic functioning. The process includes 
the main scheme up to a detailed and complex hospi-
tal treatment. The main research problem was to 
demonstrate the length and composition of the current 
Polish diagnostic process for two most risky condi-
tions, i.e. ovarian carcinoma and lung cancer, as well 
as to determine the causes for this. The results of this 
application study are models of the treatment process 
in the indicated cases with organizational changes, 
encompassing all possible types of contact between 
the patient and the healthcare system. These models 
are a pilot undertaking that ought to be popularized if 
the results described in the conclusions, which depict 
an optimal development path for Polish personalized 
medicine, are desired. 
2 LITERATURE REVIEW 
An optimal diagnostic process, i.e. a process which is 
as short as possible and leads to establishing an accu-
rate diagnosis, is an important factor, not only for the 
time of recovery and re-initiation of professional ac-
tivity, which lowers losses for the economy, but also 
for the efficacy of subsequent treatment (Rivera et al., 
2013). Diagnosis, proper inpatient treatment and in-
dividualized post-hospital therapy are subprocesses 
that comprise one diagnostic and therapeutic process 
of a given disease, occurring in certain specified con-
ditions of the healthcare system in a given country. 
The diversification of processes in terms of their du-
ration results from both the type of disease and its 
stage of progression. That is why optimization must 
be conducted for a given process that encompasses 
the subprocesses of diagnosis and treatment proper 
for a given disease. Diseases that pose the greatest 
challenge in establishing a rapid diagnosis include 
ovarian carcinoma and lung cancer. In these cases, 
improvement of time needed to make a diagnosis 
seems to be of fundamental significance due to the 
fact that initial symptoms are not necessarily specific, 
and the efficacy of the proper treatment strongly de-
pends on the time of its initiation (Havrileskya et al., 
2009). The issue of optimizing the diagnostic process 
in ovarian and lung cancers is not new (Evans et al., 
2007; Collins et al., 2007). Good practice concerning 
optimal organization of the diagnostic process in 
terms of its duration and establishing an accurate di-
agnosis vary depending on a country. This results 
from the diversity of healthcare systems. They can be 
helpful in identifying the major barriers on the way to 
proper diagnosis and treatment. Obviously, they can-
not eliminate all barriers and are not ready instru-
ments for optimal solutions in other healthcare sys-
tems (Evans et. al., 2007). 
3 MATERIALS AND METHODS 
In real environments, it is common to deal with pro-
cess characterized by incremental development, fol-
lowed by agile approaches and time improved meth-
ods such as Critical Path Method (CPM). For this rea-
son, the processes under research have to be consid-
ered to be continuous (Kunze et al., 2016). This iter-
ative approach to the process re-thinking along with 
organizational change of both the structure and the 
outcomes of a process is often referred to as process 
re-engineering. In the presented solution, the process 
will be change in order to time-improvement all steps 
of diagnostic part of process. As a result, the treat-
ment can be start at earliest opportunity with using the 
same medical assets. 
3.1 Conceptual Framework and  
Assumptions 
Improvement of the diagnostic and therapeutic pro-
cess requires an individual approach to the process 
that consists of various consecutive events. This study 
is an attempt to identify and design organizational 
changes aiming at shortening the duration of diagnos-
ing ovarian and lung cancers using existing material 
and non-material resources, on the basis of the opti-
mization of current treatment processes of these dis-
eases. Therapy in ovarian and lung cancers consists 
of three subprocesses: diagnosis, hospital treatment 
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and individual post-hospital therapy. Since the main 
aim of the study is to optimize the duration of the di-
agnostic subprocess, it was necessary to obtain de-
tailed data concerning this subprocess, which is a part 
of the patient treatment process. 
3.2 Data 
In the Polish healthcare system, the therapeutic pro-
cess is different for each patient (which considerably 
prolongs the diagnostic process and treatment proper) 
instead of creating certain specific disease-and pa-
tient-based groups. Thus, data collected for the study 
were collected from two sources: the Polish 
healthcare system and patients participating in the 
therapeutic process for ovarian and lung cancers. 
These data allow to identify all possible events that 
could occur depending on: the type of physician 
whom patients consult initially, symptoms that are 
identified and the number of specialists that can take 
part in the diagnostic process. At the same time, the 
minimum and maximum time periods associated with 
awaiting individual actions were distinguished. 
3.3 Methods 
Management sciences currently have at their disposal 
computer tools for process management. These make 
use of standards enabling description of various pro-
cesses characterized by variable complexity (Ouyang 
et al., 2008; Grosskopf et al., 2009). The application 
of these tools is not limited to business processes 
only. In particular, the Business Process Management 
Notation (BPMN) standard can be used for descrip-
tion, simulation and optimization of diagnostic and 
therapeutic processes (Allweyer, 2008; White, Bock, 
2011). Process optimization and its associated modi-
fication not only allow to identify bottlenecks, but al-
lows the entire process to be accelerated, but also give 
opportunities to obtain clues aiming at process recon-
figuration in accordance with the value-driven ap-
proach (Thomas et al., 2010; Bollen, 2016, Combi et 
al., 2017). The application of this method entailed the 
performance of the following actions in successive 
sequences. 1. Based on the data obtained, three ther-
apeutic processes were modeled in the dedicated soft-
ware: for ovarian carcinoma treatment if the patient 
initially consulted a PCP; for ovarian carcinoma treat-
ment if the patient initially consulted a gynecologist; 
and for lung cancer treatment when the patient re-
ported to a PCP. The models consisted of all events 
and time delays of their performance in the diagnostic 
subprocess. The remaining subprocesses (treatment 
proper and individualized post-hospital therapy) were 
presented in the models in the global form, as envis-
aged by the standard adopted. 2. Each process was 
then simulated in each possible variant according to 
minimum and maximum time that lapse from the ini-
tial patient appointment up to the moment of referring 
to hospital for treatment, which is equivalent to spec-
ifying a point for establishing a diagnosis. 3. The di-
agnostic subprocess was improved for each model of 
the treatment process. 4. The model of improved di-
agnosis for all three treatment processes was designed 
and verified. The obtained models of treatment pro-
cesses and results of conducted optimization served 
for forming final conclusions and indicating the need 
for further research. 
4 RESULTS 
Each of the models encompasses all possible types of 
patient-healthcare system contact, organized in the 
form of events in accordance with the BPMN stand-
ard in swimlane diagrams (Ryan, et al., 2009; White 
et al., 2011; Scheuerlein et at., 2012, Combi et al., 
2017), starting with the initial visit up to the conclu-
sion of post-hospital individual treatment and a return 
to effective professional activity. The following sub-
sections present individual models for three processes 
dedicated to treatment of ovarian and lung cancers. 
4.1 Model of Ovarian Cancer  
Treatment Process – The First Visit 
at a PCP Office 
The first model (Figure 1) presents possible paths of 
contact between an ovarian cancer patient and the 
healthcare system assuming that her first visit in the 
diagnostic subprocess took place in a PCP office. 
Solid lines denote a typical course of events (connec-
tion between events). Dashed lines, however, show 
the flow of information concerning test results. After 
each medical consultation with any type of doctor, al-
ternative decisions that the doctor could make are pre-
sented. The remaining subprocesses, being a part of 
the treatment process but not the subject of investiga-
tion, are marked and described as follows:  
1. Treatment of other diseases – both the PCP and 
any specialist (apart from geneticist) can diagnose 
diseases other than ovarian cancer and initiate a 
subprocess of treatment at any stage of the pro-
cess.  
2. Inpatient treatment – each of the doctors partici-
pating in the diagnostic process (apart from  
geneticist) can diagnose ovarian  cancer  based  on  
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Figure 1: Model of ovarian cancer treatment process – the 
first visit at a PCP office. 
data achieved or obtained in examinations and refer 
patients to hospital for proper inpatient treatment. 3. 
Post-hospital personal therapy – it is a subprocess of 
individual post-hospital treatment after the conclu-
sion of the inpatient ovarian cancer treatment. The in-
dividual stages of the diagnostic process involve time 
delay, marked as D. As the model suggests, 33 maxi-
mum delays, which may negatively affect effective 
treatment, were identified. The model contains the 
maximum number of possible events in the diagnostic 
subprocess. The stages of specialist consultations can 
be repeated and their number depends on the number 
of specialists engaged in the diagnostic process. 
Events in the form of specialist appointments as con-
secutively referred by a PCP are therefore possible. 
Moreover, each specialist can repeatedly refer the pa-
tient for specialist tests proper for that doctor’s spe-
cialty, according to their qualifications. This entails 
multiple events in terms of laboratory testing. A re-
ferral for specialist examinations entails another spe-
cialist visit upon receipt of test results. If there are no 
signs of a disease belonging to the field of expertise 
of a given specialist, the patient is again referred to a 
PCP who, in turn, refers her for further examinations 
(in the case of issuing a referral to hospital, all exam-
inations are conducted there). The delay in this model 
strictly depends on the events in the process and con-
cern the periods of awaiting: appointments with indi-
vidual physicians; performance of examinations; ob-
taining test results and admission to hospital. The 
model (Figure 1) contains a description of actions 
conducted by four specialists to whom the patient 
may be referred by a PCP: geneticist, gastrologist, on-
cologist and gynecologist. Minimum and maximum 
delay values, based on obtained data and simulations, 
are presented in Table 1. 
Table 1: Delay in waiting for doctor appointments- ovarian 
cancer treatment - first visit at a PCP office. 
Specialist 
Wait time 
for visit-
min (days) 
Wait time 
for visit-
max (days) 
Delay time 
PCP 1 7 
D6, D7, 
D11, D12, 
D19, D20, 
D29, D30 
Gastrologist 90 120 D9 
Geneticist 30 180 D3 
Oncologist 14 90 D18 
Gynecologist 2 14 D28 
As indicated by the data and calculations presented in 
Table 1, the shortest period of awaiting a visit con-
cerns a PCP – 1 day. The longest period of waiting 
for an appointment with a specialist among the mini-
mum waiting periods concerns a gastrologist: 90 
days. The longest possible time of awaiting consulta-
tion concerns a geneticist and may reach even 180 
days. The shortest and the fastest treatment path in 
terms of the number of events occurs when the patient 
is referred to hospital during the first PCP appoint-
ment. Such situations are nearly non-existent in prac-
tice since this disease does not produce specific signs 
in early stages. The longest treatment path involves 
subsequent referrals to all specialists engaged in the 
treatment process. If the patient is referred by a spe-
cialist for further examinations, the second appoint-
ment with this specialist is delayed at least by the time 
of awaiting test results. Specialist examinations are 
another source of delay. This concerns both the date 
of their performance and awaiting results. Table 2 
presents delay periods for each patient’s appointment. 
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Table 2: Delay in awaiting tests and results in the model of 
ovarian cancer diagnosis and treatment – the first visit at a 
PCP office. 
Referring physician appoint-
ment 
Result – 
min (days) 
Result – 
max 
(days) 
PCP or Gynecologist 1 2 
Oncologist or Gynecologist 7 14 
PCP or Gynecologist 14 28 
PCP or Gynecologist 1 2 
PCP or Gynecologist or On-
cologist 5 10 
PCP or Gynecologist 1 7 
Oncologist or Gynecologist 30 120 
Oncologist or Gynecologist 30 180 
Gastrologist or Oncologist 30 180 
Geneticist 180 180 
The delay time contains time delay points marked as 
“D” included in the first model (Figure 1) for duration 
of waiting for examinations and test results, respec-
tively. The duration of delays ends with the duration 
of waiting for hospital admission. Since a referral to 
hospital can be issued by any physician, this delay can 
occur at various points during the diagnostic subpro-
cess. They are identified as: D1, D10, D15, D16, D17, 
D23, D24, D25, D26, D27, D33. These delays will 
certainly occur only once in the diagnostic process. 
The time of awaiting hospital admission ranges from 
1 to 14 days. Moreover, during each visit a PCP, 
based on test results, may decide that: 1) there are no 
signs of a severe disease that would require further 
processes in the healthcare system; 2) there is a need 
to initiate a different treatment subprocess; 3) there is 
a need for hospital treatment. 
4.2 Model of Ovarian Cancer  
Treatment Process – The First Visit 
at a Gynecologist Office 
Figure 2 presents a model of ovarian cancer diagnos-
tic and therapeutic process when the patient first re-
ports to a gynecologist. The second model (Figure 2) 
was drawn up based on the approach adopted in Fig-
ure 1. As the model suggests, if the patient reports 
first to a gynecologist, the number of specialists to 
whom she can be referred is lower. This also means 
that the number of possible laboratory examinations 
is lower, but the number of tests remains unchanged. 
In the entire diagnostic subprocess, 25 delays were 
noted. This number is lower by 8 compared with the 
previous model. Table 3 presents delay in awaiting 
doctor appointment in the model of ovarian cancer di-
agnosis and treatment when the first visit took place 
at a gynecologist office. The longest period of waiting 
for an appointment among the cases with the lowest 
time periods concerns a gastrologist: 90 days. 
Table 3: Delay in waiting for doctor appointments- ovarian 
cancer treatment - the first visit at a gynecologist office. 
Specialist 
Wait time 
for visit-
min (days) 
Wait time 
for visit-
max (days) 
Delay time 
Gynecologist 2 14 
D6, D7, 
D11, D12, 
D19, D20 
Gastrologist 90 120 D9 
Geneticist 30 180 D3 
Oncologist 14 90 D18 
As indicated by the data and calculations presented in 
Table 3, the shortest period of awaiting a visit con-
cerns a gynecologist: 2 days. 
 
Figure 2: Model of ovarian cancer treatment process – the 
first visit at a gynecologist office. 
The longest possible time of awaiting consultation 
concerns a geneticist and may reach even 180 days. 
Compared with the model shown in Figure 1 (the first 
visit – PCP), the range of delay did not change con-
siderably, but the entire diagnostic subprocess is 
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shorter by one gynecological consultation, which 
saves 2 to 180 days. This results from the possibility 
of being referred for specialist examinations as soon 
as during the very first visit (by a gynecologist). The 
remaining delays in other segments of this process 
still lower chances for effective treatment. The short-
est path in terms of the number of events and, at the 
same time, the fastest treatment route takes place 
when a gynecologist refers the patient to hospital at 
the very first visit. Such situations are rare in practice 
because symptoms of ovarian cancer would then in-
dicate advanced disease, the treatment of which is 
poorly effective. The longest treatment path involves 
subsequent referrals to all specialists engaged in the 
treatment process. As in the previous model, if the pa-
tient is referred for further examinations by a special-
ist, the second appointment with this specialist is de-
layed at least by the time of awaiting test results. Spe-
cialist examinations are another source of delay. This 
concerns both the date of their performance and 
awaiting results. Table 4 presents delay periods for 
each patient’s appointment. The delay time contains 
time delay points marked as “D” included in the sec-
ond model (Figure 2) for duration of waiting for ex-
aminations and test results, respectively. The total de-
lay ends with the duration of waiting for hospital ad-
mission. Since a referral to hospital can be issued by 
any physician, this delay can occur at various points 
during the diagnostic subprocess. They are marked 
as: D1, D10, D15, D16, D17, D23, D24, D25. 
Table 4: Delay in awaiting tests and results in the model of 
ovarian cancer diagnosis and treatment – the first visit at a 
gynecologist office. 
Referring physician appoint-
ment 
Result- 
min (days) 
Result- 
max 
(days) 
Gynecologist 1 2 
Gynecologist or Oncologist 7 14 
Gynecologist 14 28 
Gynecologist 1 2 
Gynecologist or Oncologist 5 10 
Gynecologist 1 7 
Gynecologist or Oncologist 30 120 
Gynecologist or Oncologist 30 180 
Gastrologist or Oncologist 30 180 
Geneticist 180 180 
These delays will certainly occur only once in the di-
agnostic process. As in the previous model, the time 
of awaiting hospital admission ranges from 1 to 14 
days. Moreover, during each visit a gynecologist, 
based on test results, may decide that there are no 
signs of a severe disease that would require further 
processes in the healthcare system, there is a need to 
initiate a different treatment subprocess or that there 
is a need for hospital treatment. 
4.3 Model of Lung Cancer Treatment 
Process 
Figure 3 presents a model of lung cancer diagnostic 
and therapeutic process. The third model (Figure 3) is 
also based on Figure 1 (first visit at a PCP office). 
 
Figure 3: Model of lung cancer diagnostic and therapeutic 
process. 
It is characterized by a lower number of specialists to 
whom patients may be referred. This also means that 
the number of possible laboratory examinations is 
lower, but the number of tests remains unchanged. In 
the entire diagnostic process, 25 delays were noted. 
This number is lower by 8 compared with the previ-
ous model (Figure 1). Table 5 presents delay in await-
ing doctor appointment in the model of lung cancer 
diagnosis and treatment. As indicated by the data and 
calculations presented in Table 5, the shortest period 
of awaiting a visit concerns a PCP: 1 day. The shortest 
and the fastest treatment path in terms of the number 
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of events occurs when the patient is referred to hospi-
tal during the first PCP appointment. Such situations 
are rare in practice because first symptoms of lung 
cancer are non-specific and require additional, some-
times numerous, examinations. 
Table 5: Delay in awaiting doctor appointment in the model 
of lung cancer diagnosis and treatment. 
Specialist 
Wait time 
for visit-
min (days) 
Wait time 
for visit-
max (days) 
Delay time 
PCP 1 7 
D6, D7, 
D11, D12, 
D19, D20 
Geneticist 30 180 D3 
Oncologist 14 90 D9 
Pulmonologist 14 120 D18 
The longest period of waiting for an appointment 
among the events with the shortest time periods con-
cerns a geneticist: 30 days. The longest possible time 
of awaiting consultation also concerns a geneticist 
and may reach even 180 days. The longest treatment 
path involves subsequent referrals to all specialists 
engaged in the treatment process. As in the previous 
models, if the patient is referred for further examina-
tions by a specialist, the second appointment with this 
specialist is delayed at least by the time of awaiting 
test results. Specialist examinations are another 
source of delays. This concerns both the date of their 
performance and awaiting results. Table 6 presents 
types of examinations and delay periods that they en-
tail. 
Table 6: Delay in awaiting tests and results in the model of 
lung cancer diagnosis and treatment. 
Referring physician appoint-
ment 
Result – 
min 
(days) 
Result – 
max 
(days) 
PCP 1 2 
PCP 14 28 
PCP or Oncologist 1 7 
PCP or Oncologist or Pul-
monologist 30 120 
Oncologist or Pulmonologist 1 7 
Oncologist or Pulmonologist 31 62 
Pulmonologist 30 180 
Pulmonologist 7 14 
Geneticist 180 180 
The delay time contains time delay points marked as 
“D” included in the second model (Figure 3) for du-
ration of waiting for the examination and test results, 
respectively. The delay ends with the duration of 
waiting for hospital admission. They are marked as: 
D1, D10, D15, D16, D17, D23, D24, D25. The time 
of awaiting hospital admission occurs only once and 
ranges from 1 to 14 days. During each visit, a PCP, 
based on test results, may decide that there is a need 
to initiate a different treatment subprocess or that 
there is a need for hospital treatment. The PCP can 
also diagnose a minor disease or prescribe certain 
medications, after which the patient leaves the 
healthcare system. 
4.4 Improved Model of Ovarian and 
Lung Cancer Treatment 
The model simulations yielded results presented in 
Table 7. It was assumed that all necessary examina-
tions will be conducted in an optimal way, i.e. without 
extending the waiting period associated with their 
performance and receiving results. That is why the 
delay ranges from 1 to 180 days in each of the ana-
lyzed models. Also, delay associated with the initial 
PCP or gynecological visit are not taken into consid-
eration in the simulation since, in this case, the patient 
makes decisions irrespective of the system in which 
treatment is conducted. As simulations suggest (Table 
7), the longest delay is generated by repeatable loops 
of appointments with specialists. A question arises: 
Can the duration of the diagnostic process in ovarian 
and lung cancer be shortened significantly using the 
present resources of the healthcare system? The sim-
ulations indicate that two organizational changes may 
be performed: 1. Broadening the scope of PCP quali-
fications in terms of referring patients for specialist 
examinations, involving oncological, gynecologic 
and gastrological tests. 2. Organizing online medical 
conferences with specialists that would have access to 
all data that a PCP has obtained from the patient and 
to results of tests from within their fields of expertise. 
Following such a conference, a PCP can inform the 
patient about the results of the conference and refer 
them to hospital for treatment even during the second 
visit. These two organizational changes served for de-
signing an improved model of ovarian and lung can-
cer treatment (Figure 4). First of all, the scope of PCP 
and gynecologist qualifications must be broadened so 
that patients could be referred for examinations dur-
ing the first appointments. The range of tests should 
include the most significant tests conducted by an on-
cologist, gastrologist, geneticist and pulmonologist. 
The PCP should have the power to refer patients for 
gynecological examinations if symptoms suggest 
ovarian cancer. When all tests have been conducted 
in accordance with the initial diagnosis of ovarian or 
lung cancer it is necessary to organize an online med-
ical conference without the need for the patient pres-
ence. Physicians that must take part in the conference 
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Table 7: Simulations of ovarian and lung cancer treatment model. 
Model Event Wait time for visit- min (days) 
Wait time for visit -
max (days) Designation 
Model of ovar-
ian cancer treat-
ment process – 
the first visit at 
a PCP office 
4 PCP visits 4 28 
Delay concerning visits 
is presented in Table 1 
1st visits to 4 specialists 136 404 
2nd visits to 4 specialists 136 404 
Admission to hospital 1 14 
Total 277 940 
Perform and obtain test results 1 180 
Delay concerning tests 
is presented in Table 2 
Total visits and examinations 278 1120 N/A 
Model of ovar-
ian cancer treat-
ment process – 
the first visit at 
a gynecologist 
office 
4 visits to the gynecologist 8 72 
Delay concerning visits 
is presented in Table 3 
1st visits to 3 specialists 134 390 
2nd visits to 3 specialists 134 390 
Admission to hospital 1 14 
Total 267 866 
Perform and obtain test results 1 180 
Delay concerning tests 
is presented in Table 4 
Total visits and examinations 268 1046 N/A 
Model of lung 
cancer treat-
ment process – 
the first visit al-
ways takes 
place at a PCP 
office 
4 PCP visits 4 28 
Delay concerning visits 
is presented in Table 5 
1st visits to 3 specialists 58 390 
2nd visits to 3 specialists 58 390 
Admission to hospital 1 14 
Total 121 822 
Perform and obtain test results 1 180 
Delay concerning tests 
is presented in Table 6 
Total visits and examinations 122 1002 N/A 
 
include: a PCP, oncologist and, depending on the sus-
pected disease: gynecologist and gastrologist for 
ovarian cancer, or pulmonologist and thoracic sur-
geon for lung cancer 
 
Figure 4: Improved model of ovarian and lung cancer diag-
nostic and therapeutic process. 
Doctors taking part in such an online medical confer-
ence have access to all data collected by the PCP dur-
ing the first visit and to all test results. The conference 
can be organized using standard and generally avail-
able tools for a video conference. Eventually, such 
conferences will be held regularly as the work on 
computerization of the health system progresses will 
continue with application of appropriate security 
measures. Doctors can make the following decisions: 
1. The patient is healthy; 2. Admission to hospital; 3. 
Depending on the diagnosis, initiation of treatment 
for diseases other than ovarian or lung cancer. The 
application of the proposed solution to the treatment 
process of lung and ovarian cancer will reduce the 
time of awaiting appointments with specialists. The 
simulations of the optimal model of ovarian and lung 
cancer diagnostic and therapeutic process yielded re-
sults presented in Table 8. For the simulation condi-
tions to be identical to those in the previous models, 
it was assumed that all necessary examinations will 
be conducted in the optimal way, i.e. without extend-
ing the waiting period associated with their perfor-
mance and receiving results. That is why the delay 
ranges from 1 to 180 days in each of the analyzed 
models. Delay associated with the initial PCP visit are 
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Table 8: Results of simulations of the optimal model of ovarian and lung cancer diagnosis and treatment. 
Disease Event Wait time for visit-min (days) 
Wait time for visit- 
max (days) Designation 
Improved model of 
ovarian cancer treat-
ment process – the 
first visit at a PCP 
office 
One PCP visit 1 7 D9 
One visit with a geneticist 30 180 D3 
Medical conference 106 224 D6, D7 
Admission to hospital 1 14 D1, D10 
Total 138 425 N/A 
Perform and receive test results 1 180 D2, D4, D5, D8 
Total visits and examinations 139 605 N/A 
Improved model of 
ovarian cancer treat-
ment process – the 
first visit at a gyne-
cologist office 
One visit to a gynecologist 2 14 D9 
One visit to a geneticist 30 180 D3 
Medical conference 104 210 D6, D7 
Admission to hospital 1 14 D1, D10 
Total 137 404 N/A 
Perform and receive test results 1 180 D2, D4, D5, D8 
Total visits and examinations 138 584 N/A 
Improved model of 
lung cancer treatment 
process – the first 
visit always takes 
place at a PCP office 
One PCA visit 1 7 D9 
One visit to a geneticist 30 180 D3 
Medical conference 28 210 D6, D7 
Admission to hospital 1 14 D1, D10 
Total 60 411 N/A 
Perform and receive test results 1 180 D2, D4, D5, D8 
Total visits and examinations 61 591 N/A 
 
not taken into consideration in the simulation since, 
in this case, the patient makes decisions irrespective 
of the system in which treatment is conducted. When 
conducting the simulation, all data concerning delay 
calculated in all models for doctor appointments, per-
formance of examinations and obtaining test results 
as well as admission to hospital were used. 
5 DISCUSSION AND  
CONCLUSIONS 
The work presented in this paper demonstrates that 
organizational changes could reduce the number of 
delays in the diagnostic and therapeutic process of 
ovarian and lung cancer from 33 and 25, respectively, 
to 10 in both cases with using the same number of 
specialists and other medical staff. Moreover, it al-
lowed the application of one standardized diagnostic 
subprocess where the difference between diseases 
only involves different sets of specialist examinations 
and a different team of physicians taking part in the 
medical conference. Upon the introduction of 
changes, the improved model preserves the shortest 
possible diagnostic path by the possibility of issuing 
a referral to hospital even during the first visit. The 
simulation of the improved model for ovarian cancer 
diagnosis and treatment with the first visit at a PCP 
office indicates that the minimum time was reduced 
from 278 to 139 days, and the longest possible time 
of staying within the healthcare system – from 1120 
to 605 days. This means reductions in the time from 
the first PCP visit to hospital admission by 50% and 
46%, respectively. In the case of the first patient visit 
at a gynecologist office, the minimum time was re-
duced from 268 to 138 days, and the maximum time 
– from 1046 to 584 days. This means reductions in 
the time from the first appointment with a gynecol-
ogist to hospital admission by 48.5% and 44.17%, re-
spectively. As for the simulation of the optimal model 
for lung cancer diagnosis and treatment, the minimum 
time was reduced from 122 to 61 days, and the longest 
possible time – from 1002 to 591 days. This means 
reductions in the time from the first PCP visit to hos-
pital admission by 50% and 41%, respectively. Con-
sidering the results reported above, it can be stated 
that introducing organizational changes (for now 
without making investments in the fixed assets and 
equipment), in the form of broadening the scope of 
PCP and gynecologist qualifications in terms of issu-
ing referrals for specialist examinations as well as or-
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ganizing regular medical conferences online depend-
ing on the type of symptoms and initial PCP diagno-
sis, helps save approximately 50% of time in the sub-
process of ovarian and lung cancer diagnosis. These 
results enable earlier decisions about referring pa-
tients for proper personalized treatment. Organizing 
online medical conferences without the need for the 
patient presence will reduce lines to specialists since 
in many cases, decisions will be made during the con-
ference. Reductions in the time that would otherwise 
be devoted to awaiting appointments with specialists 
is another long-term effect of the aforementioned or-
ganizational innovation. Essential investments must 
be made within the Information and Communication 
Technologies (ICT) (rapid communication, online 
conferences). It is an example of how the ICT can be 
used in the process of diagnostic and treatment in or-
der to reduce time for diagnostic and start personal-
ized therapy as soon as possible. Without additional 
investments in specialists and medical staff, a sub-
stantial time-optimization of process brings about 
50% of diagnostic time reduction. 
6 FUTURE RESEARCH 
The subsequent stage of improvement management 
should involve the performance of preliminary re-
search and making a selection of facilities that per-
form specialist laboratory tests in order to shorten 
procedures and examinations, as well as reduce the 
time of waiting for test results (they should be avail-
able instantaneously). Another challenge for the pre-
sent healthcare system is the introduction of an inte-
grated database in which patient data and their entire 
medical histories could be stored. The issues pre-
sented above should constitute new research and im-
plementation projects that need to be undertaken as 
soon as possible. 
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